Yutrepia
Payments companies reported to CMS as associated with Yutrepia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Yutrepia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Yutrepia
These are the largest totals companies reported as associated with Yutrepia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Edwin Parsley | Houston, TX | Critical Care Medicine (Internal Medicine) | $22,733.75 |
| Richard Channick | Boston, MA | Critical Care Medicine (Internal Medicine) | $301.95 |
| Rajan Saggar | Los Angeles, CA | Pulmonary Disease | $301.94 |
| Vallerie Mclaughlin | Ann Arbor, MI | Cardiovascular Disease | $280.36 |
| Sandeep Sahay | Houston, TX | Pulmonary Disease | $253.03 |
| Michael Risbano | Pittsburgh, PA | Critical Care Medicine (Internal Medicine) | $226.12 |
| Kelly Marcello | Phoenix, AZ | Family | $189.22 |
| Naomi Habib | Phoenix, AZ | Critical Care Medicine (Internal Medicine) | $189.20 |
| Roxana Sulica | New York, NY | Critical Care Medicine (Internal Medicine) | $165.58 |
| Sonja Bartolome | Dallas, TX | Pulmonary Disease | $165.57 |
Prescribed Yutrepia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.